Antitumor Assessment: Publications

Elisa de Stanchina (Core Head)

Antitumor Assessment: Publications

Elisa de Stanchina (Core Head)


Maddalo, D. et al. (2014). “In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system”. Nature 516: 423-7. PMID: 25337876

Schwartz, S. et al. (2014). Feedback suppression of PI3Kα signaling in PTEN negative tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell  27:109-22. PMID: 25544636

Lovly, CM. et al. (2014). “Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.” Nat Med. 20:1027-34 PMID: 25173427

Huang, CH. et al. (2014). “CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma”. Genes Dev. 15:1800-14 PMID:25128497

Wolfe, A. et al. (2014). “RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer”. Nature 513: 65-70 PMID: 25079319

Will, M. et al. (2014). “Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling”. Cancer Discov. 4:334-47. PMID: 24436048

Clohessy, J. G and de Stanchina, E. (2013). “Infrastructure needs for translational integration of mouse and human trials”. Mouse Models of Cancer, CSHL Press: 461-66. PMID: 24173312

Piovan, E. et al.  (2013). “Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia”. Cancer Cell 24:766-76 PMID: 24291004 PMCID: PMC3878658

Janjigian, YY. et al. (2013). “Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET”. J Nucl Med 54: 936-43 PMID: 23578997

Lito, P. et al. (2012). “Relief of profound feedback inhibition of mitogenic signaling by Raf inhibitors attenuates their activities in BRAFV600E melanomas”. Cancer Cell 22:668-82

Luke, JJ. et al. (2012). “The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and phase I clinical trial.” Clin Cancer Res. 18: 2638-47

Clegg, NJ. et al. (2012). “ARN-509: a novel anti-androgen for prostate cancer treatment.” Cancer Res.  72:1494-503

Zammarchi, F. et al. (2011). “Anti-tumorigenic potential of STAT3 alternative splicing modulation”. Proc. Natl. Acad. Sci.USA 108-17779-84

Benezra M. et al. (2011) “Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.” J Clin Invest. 121:2768-80

Koppikar, P. et al. (2010). “Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis” Blood 115:2919-2927.

Mu, P. et al. (2009). “Genetic dissection of the MiR17 approximately 92 cluster of microRNAs in Myc-induced B-cell lymphomas”. Genes Dev. 23: 2806-11.

Regales, L. et al. (2009). “Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer”. J. Clin. Invest. 119:3000-3010.

Caldas-Lopes, E. (2009). “Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models”. Proc. Natl. Acad. Sci.USA 106: 8368-8673.

Real, P.J. et al.  (2009). “Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL”. Nature Med. 15: 50-58.